{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T06:23:39Z","timestamp":1789712619683,"version":"4.0.1"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T00:00:00Z","timestamp":1604275200000},"content-version":"vor","delay-in-days":306,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Therapeutic options for patients with treatment-resistant epilepsy represent an important unmet need. Addressing this unmet need was the main factor driving the drug discovery program that led to the synthesis of padsevonil, a first-in-class antiepileptic drug candidate that interacts with two therapeutic targets: synaptic vesicle protein 2 and GABAA receptors. Two PET imaging studies were conducted in healthy volunteers to identify optimal padsevonil target occupancy corresponding to levels associated with effective antiseizure activity in rodent models. Optimal padsevonil occupancy associated with non-clinical efficacy was translatable to humans for both molecular targets: high (&amp;gt;90%), sustained synaptic vesicle protein 2A occupancy and 10\u201315% transient GABAA receptor occupancy. Rational dose selection enabled clinical evaluation of padsevonil in a Phase IIa proof-of-concept trial (NCT02495844), with a single-dose arm (400\u2009mg bid). Adults with highly treatment-resistant epilepsy, who were experiencing \u22654 focal seizures\/week, and had failed to respond to \u22654 antiepileptic drugs, were randomized to receive placebo or padsevonil as add-on to their stable regimen. After a 3-week inpatient double-blind period, all patients received padsevonil during an 8-week outpatient open-label period. The primary endpoint was \u226575% reduction in seizure frequency. Of 55 patients randomized, 50 completed the trial (placebo n\u2009=\u200926; padsevonil n\u2009=\u200924). Their median age was 36\u2009years (range 18\u201360), and they had been living with epilepsy for an average of 25\u2009years. They were experiencing a median of 10 seizures\/week and 75% had failed \u22658 antiepileptic drugs. At the end of the inpatient period, 30.8% of patients on padsevonil and 11.1% on placebo were \u226575% responders (odds ratio 4.14; P\u2009=\u20090.067). Reduction in median weekly seizure frequency was 53.7% and 12.5% with padsevonil and placebo, respectively (unadjusted P\u2009=\u20090.026). At the end of the outpatient period, 31.4% were \u226575% responders and reduction in median seizure frequency was 55.2% (all patients). During the inpatient period, 63.0% of patients on placebo and 85.7% on padsevonil reported treatment-emergent adverse events. Overall, 50 (90.9%) patients who received padsevonil reported treatment-emergent adverse events, most frequently somnolence (45.5%), dizziness (43.6%) and headache (25.5%); only one patient discontinued due to a treatment-emergent adverse event. Padsevonil was associated with a favourable safety profile and displayed clinically meaningful efficacy in patients with treatment-resistant epilepsy. The novel translational approach and the innovative proof-of-concept trial design maximized signal detection in a small patient population in a short duration, expediting antiepileptic drug development for the population with the greatest unmet need in epilepsy.<\/jats:p>","DOI":"10.1093\/braincomms\/fcaa183","type":"journal-article","created":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T08:41:09Z","timestamp":1604306469000},"source":"Crossref","is-referenced-by-count":28,"title":["Padsevonil randomized Phase IIa trial in treatment-resistant focal epilepsy: a translational approach"],"prefix":"10.1093","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3973-8606","authenticated-orcid":false,"given":"Pierandrea","family":"Muglia","sequence":"first","affiliation":[{"name":"UCB Pharma, Braine l\u2019Alleud, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Hannestad","sequence":"additional","affiliation":[{"name":"UCB Pharma, Braine l\u2019Alleud, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Brandt","sequence":"additional","affiliation":[{"name":"Department of General Epileptology, Bethel Epilepsy Centre, Mara Hospital, Bielefeld, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"DeBruyn","sequence":"additional","affiliation":[{"name":"UCB Pharma, Braine l\u2019Alleud, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Germani","sequence":"additional","affiliation":[{"name":"UCB Pharma, Braine l\u2019Alleud, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Lacroix","sequence":"additional","affiliation":[{"name":"UCB Pharma, Braine l\u2019Alleud, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian","family":"Majoie","sequence":"additional","affiliation":[{"name":"Department of Neurology, Academic Center of Epileptology Kempenhaeghe, Maastricht University Medical Centre, Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Otoul","sequence":"additional","affiliation":[{"name":"UCB Pharma, Braine l\u2019Alleud, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Sciberras","sequence":"additional","affiliation":[{"name":"UCB Pharma, Braine l\u2019Alleud, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard J","family":"Steinhoff","sequence":"additional","affiliation":[{"name":"Kork Epilepsy Center, Kehl-Kork, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen","family":"Van Laere","sequence":"additional","affiliation":[{"name":"Department of Imaging and Pathology, KU, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"Van Paesschen","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospital, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Webster","sequence":"additional","affiliation":[{"name":"UCB Pharma, Raleigh, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafal M","family":"Kaminski","sequence":"additional","affiliation":[{"name":"UCB Pharma, Braine l\u2019Alleud, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konrad J","family":"Werhahn","sequence":"additional","affiliation":[{"name":"UCB Pharma, Monheim am Rhein, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Toledo","sequence":"additional","affiliation":[{"name":"Epilepsy Unit, Department of Neurology, Vall d'Hebron Hospital, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,11,2]]},"reference":[{"key":"2020112001363151300_fcaa183-B1","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0014-2999(95)00633-8","article-title":"Central benzodiazepine receptor occupancy by zolpidem in the human brain as assessed by positron emission tomography","volume":"295","author":"Abadie","year":"1996","journal-title":"Eur J Pharmacol"},{"key":"2020112001363151300_fcaa183-B2","first-page":"357","volume-title":"Radiopharmaceuticals and brain pathology studied with PET and SPECT","author":"Abadie","year":"1990"},{"key":"2020112001363151300_fcaa183-B3","first-page":"5","article-title":"Basic pharmacologic mechanisms involved in benzodiazepine tolerance and withdrawal","volume":"8","author":"Bateson","year":"2002","journal-title":"Curr PD"},{"key":"2020112001363151300_fcaa183-B4","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1212\/WNL.0000000000002864","article-title":"Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies","volume":"87","author":"Ben-Menachem","year":"2016","journal-title":"Neurology"},{"key":"2020112001363151300_fcaa183-B5","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1001\/jamaneurol.2017.3949","article-title":"Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study","volume":"75","author":"Chen","year":"2018","journal-title":"JAMA Neurol"},{"key":"2020112001363151300_fcaa183-B6","first-page":"5","article-title":"Animal models in translational medicine: validation and prediction","volume":"2","author":"Denayer","year":"2014","journal-title":"New Hor Transl Med"},{"key":"2020112001363151300_fcaa183-B7","doi-asserted-by":"crossref","first-page":"18024","DOI":"10.1038\/nrdp.2018.24","article-title":"Epilepsy","volume":"4","author":"Devinsky","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"2020112001363151300_fcaa183-B8","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1212\/WNL.0000000000003407","article-title":"What can we do for people with drug-resistant epilepsy? The 2016 Wartenberg Lecture","volume":"87","author":"Engel","year":"2016","journal-title":"Neurology"},{"key":"2020112001363151300_fcaa183-B9","doi-asserted-by":"crossref","first-page":"348ra96","DOI":"10.1126\/scitranslmed.aaf6667","article-title":"Imaging synaptic density in the living human brain","volume":"8","author":"Finnema","year":"2016","journal-title":"Sci Transl Med"},{"key":"2020112001363151300_fcaa183-B10","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/epi.14701","article-title":"A single-center, open-label positron emission tomography study to evaluate brivaracetam and levetiracetam synaptic vesicle glycoprotein 2A binding in healthy volunteers","volume":"60","author":"Finnema","year":"2019","journal-title":"Epilepsia"},{"key":"2020112001363151300_fcaa183-B11","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.eplepsyres.2013.04.008","article-title":"Designing a new proof-of-principle trial for treatment of partial seizures to demonstrate efficacy with minimal sample size and duration \u2013 a case study","volume":"106","author":"French","year":"2013","journal-title":"Epilepsy Res"},{"key":"2020112001363151300_fcaa183-B12","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejphar.2011.04.064","article-title":"Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties","volume":"664","author":"Gillard","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"2020112001363151300_fcaa183-B13","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.phrs.2015.12.030","article-title":"Activation-induced regulation of GABAA receptors: is there a link with the molecular basis of benzodiazepine tolerance?","volume":"109","author":"Gravielle","year":"2016","journal-title":"Pharmacol Res"},{"key":"2020112001363151300_fcaa183-B14","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.eplepsyres.2007.06.003","article-title":"Predictors of pharmacoresistant epilepsy","volume":"75","author":"Hitiris","year":"2007","journal-title":"Epilepsy Res"},{"key":"2020112001363151300_fcaa183-B15","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1111\/j.1528-1167.2009.02089.x","article-title":"Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam","volume":"50","author":"Kaminski","year":"2009","journal-title":"Epilepsia"},{"key":"2020112001363151300_fcaa183-B16","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.neuropharm.2007.11.021","article-title":"SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy","volume":"54","author":"Kaminski","year":"2008","journal-title":"Neuropharmacology"},{"key":"2020112001363151300_fcaa183-B17","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJM200002033420503","article-title":"Early identification of refractory epilepsy","volume":"342","author":"Kwan","year":"2000","journal-title":"N Engl J Med"},{"key":"2020112001363151300_fcaa183-B18","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.yebeh.2014.05.031","article-title":"The consequences of refractory epilepsy and its treatment","volume":"37","author":"Laxer","year":"2014","journal-title":"Epilepsy Behav"},{"key":"2020112001363151300_fcaa183-B19","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1124\/jpet.119.261222","article-title":"Pharmacological profile of the antiepileptic drug candidate padsevonil \u2013 characterization in rodent seizure and epilepsy models","volume":"372","author":"Leclercq","year":"2020","journal-title":"J Pharmacol Exp Ther"},{"key":"2020112001363151300_fcaa183-B20","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.cmpb.2005.04.005","article-title":"PsN-Toolkit\u2014a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM","volume":"79","author":"Lindbom","year":"2005","journal-title":"Comput Methods Programs Biomed"},{"key":"2020112001363151300_fcaa183-B21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00213-005-0060-1","article-title":"A proof-of-concept study using [11C]flumazenil PET to demonstrate that pagoclone is a partial agonist","volume":"180","author":"Lingford-Hughes","year":"2005","journal-title":"Psychopharmacology (Berl"},{"key":"2020112001363151300_fcaa183-B22","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/nrd4126","article-title":"New avenues for anti-epileptic drug discovery and development","volume":"12","author":"L\u00f6scher","year":"2013","journal-title":"Nat Rev Drug Discov"},{"key":"2020112001363151300_fcaa183-B23","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.seizure.2011.01.003","article-title":"Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs","volume":"20","author":"L\u00f6scher","year":"2011","journal-title":"Seizure"},{"key":"2020112001363151300_fcaa183-B24","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.eplepsyres.2016.05.016","article-title":"Fit for purpose application of currently existing animal models in the discovery of novel epilepsy therapies","volume":"126","author":"L\u00f6scher","year":"2016","journal-title":"Epilepsy Res"},{"key":"2020112001363151300_fcaa183-B25","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1007\/s11064-016-2025-7","article-title":"The search for new screening models of pharmacoresistant epilepsy: is induction of acute seizures in epileptic rodents a suitable approach?","volume":"42","author":"L\u00f6scher","year":"2017","journal-title":"Neurochem Res"},{"key":"2020112001363151300_fcaa183-B26","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S0028-3908(96)00072-X","article-title":"Benzodiazepine site pharmacokinetic\/pharmacodynamic quantification in man: direct measurement of drug occupancy and effects on the human brain in vivo","volume":"35","author":"Malizia","year":"1996","journal-title":"Neuropharmacology"},{"key":"2020112001363151300_fcaa183-B27","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1038\/bjp.2008.198","article-title":"Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A","volume":"154","author":"Matagne","year":"2008","journal-title":"Br J Pharmacol"},{"key":"2020112001363151300_fcaa183-B28","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1124\/jpet.112.199794","article-title":"Translation of central nervous system occupancy from animal models: application of pharmacokientic\/pharmacodynamic modeling","volume":"347","author":"Melhem","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"2020112001363151300_fcaa183-B29","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1468-1331.2006.01215.x","article-title":"Diagnosing refractory epilepsy: response to sequential treatment schedules","volume":"13","author":"Mohanraj","year":"2006","journal-title":"Eur J Neurol"},{"key":"2020112001363151300_fcaa183-B30","doi-asserted-by":"crossref","first-page":"777","DOI":"10.2967\/jnumed.115.168179","article-title":"Synthesis and preclinical evaluation of 11C-UCB-J as a PET tracer for imaging the synaptic vesicle glycoprotein 2A in the brain","volume":"57","author":"Nabulsi","year":"2016","journal-title":"J Nucl Med"},{"key":"2020112001363151300_fcaa183-B31","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11940-016-0401-x","article-title":"The role of benzodiazepines in the treatment of epilepsy","volume":"18","author":"Ochoa","year":"2016","journal-title":"Curr Treat Options Neurol"},{"key":"2020112001363151300_fcaa183-B32","author":"Otoul","year":"2017"},{"key":"2020112001363151300_fcaa183-B33","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1212\/WNL.31.7.912","article-title":"The hospital experience and seizure control","volume":"31","author":"Riley","year":"1981","journal-title":"Neurology"},{"key":"2020112001363151300_fcaa183-B34","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1600-0404.2008.01004.x","article-title":"Benzodiazepines in epilepsy: pharmacology and pharmacokinetics","volume":"118","author":"Riss","year":"2008","journal-title":"Acta Neurol Scand"},{"key":"2020112001363151300_fcaa183-B35","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1038\/bjp.2008.221","article-title":"Brivaracetam: a rational drug discovery success story","volume":"154","author":"Rogawski","year":"2008","journal-title":"Br J Pharmacol"},{"key":"2020112001363151300_fcaa183-B36","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/nrd3502","article-title":"Beyond classical benzodiazepines: novel therapeutic potential of GABA receptor subtypes","volume":"10","author":"Rudolph","year":"2011","journal-title":"Nat Rev Drug Discov Disc"},{"key":"2020112001363151300_fcaa183-B37","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s40263-013-0129-z","article-title":"The pharmacology of imepitoin: the first partial benzodiazepine receptor agonist developed for the treatment of epilepsy","volume":"28","author":"Rundfeldt","year":"2014","journal-title":"CNS Drugs"},{"key":"2020112001363151300_fcaa183-B38","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1212\/01.wnl.0000286959.22040.6e","article-title":"Quantifying the response to antiepileptic drugs: effect of past treatment history","volume":"70","author":"Schiller","year":"2008","journal-title":"Neurology"},{"key":"2020112001363151300_fcaa183-B39","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1001\/archneurol.2009.211","article-title":"Seizure relapse and development of drug resistance following long-term seizure remission","volume":"66","author":"Schiller","year":"2009","journal-title":"Arch Neurol"},{"key":"2020112001363151300_fcaa183-B40","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/jcph.761","article-title":"Brivaracetam population pharmacokinetics and exposure-response modeling in adult subjects with partial-onset seizures","volume":"56","author":"Schoemaker","year":"2016","journal-title":"J Clin Pharmacol"},{"key":"2020112001363151300_fcaa183-B41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0014-2999(94)90149-X","article-title":"Long-term treatment with abecarnil fails to induce tolerance in mice","volume":"259","author":"Serra","year":"1994","journal-title":"Eur J Pharmacol"},{"key":"2020112001363151300_fcaa183-B42","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1111\/epi.12212","article-title":"Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies","volume":"54","author":"Steinhoff","year":"2013","journal-title":"Epilepsia"},{"key":"2020112001363151300_fcaa183-B43","doi-asserted-by":"crossref","first-page":"712","DOI":"10.3389\/fneur.2017.00712","article-title":"The burden of severely drug-refractory epilepsy: a comparative longitudinal evaluation of mortality, morbidity, resource use, and cost using German Health Insurance Data","volume":"8","author":"Strzelczyk","year":"2017","journal-title":"Front Neurol"},{"key":"2020112001363151300_fcaa183-B44","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/0028-3908(93)90080-M","article-title":"[123I]iomazenil SPECT imaging demonstrates significant benzodiazepine receptor reserve in human and nonhuman primate brain","volume":"32","author":"Sybirska","year":"1993","journal-title":"Neuropharmacology"},{"key":"2020112001363151300_fcaa183-B45","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0140-6736(18)32596-0","article-title":"Epilepsy in adults","volume":"393","author":"Thijs","year":"2019","journal-title":"Lancet"},{"key":"2020112001363151300_fcaa183-B46","author":"Van Paesschen","year":"2018"},{"key":"2020112001363151300_fcaa183-B47","first-page":"1","article-title":"Mechanisms underlying tolerance after long-term benzodiazepine use: a future for subtype-selective GABAA receptor modulators?","volume":"2012","author":"Vinkers","year":"2012","journal-title":"Adv Pharmacol Sci"},{"key":"2020112001363151300_fcaa183-B48","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/epi.12191","article-title":"Pharmacoresistant epilepsy: unmet needs in solving the puzzle (s)","volume":"54","author":"Weaver","year":"2013","journal-title":"Epilepsia"},{"key":"2020112001363151300_fcaa183-B49","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/epi.13638","article-title":"Evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein","volume":"58","author":"Wood","year":"2017","journal-title":"Epilepsia"},{"key":"2020112001363151300_fcaa183-B50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/jpet.119.261149","article-title":"Pharmacological profile of the antiepileptic drug candidate padsevonil \u2013 interactions with synaptic vesicle 2 proteins and GABAA receptors","volume":"372","author":"Wood","year":"2020","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Brain Communications"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/braincomms\/advance-article-pdf\/doi\/10.1093\/braincomms\/fcaa183\/34088129\/fcaa183.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/braincomms\/article-pdf\/2\/2\/fcaa183\/34424089\/fcaa183.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/braincomms\/article-pdf\/2\/2\/fcaa183\/34424089\/fcaa183.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,21]],"date-time":"2020-11-21T05:10:49Z","timestamp":1605935449000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/braincomms\/article\/doi\/10.1093\/braincomms\/fcaa183\/5948985"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/braincomms\/fcaa183","relation":{},"ISSN":["2632-1297"],"issn-type":[{"value":"2632-1297","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020]]},"published":{"date-parts":[[2020]]},"article-number":"fcaa183"}}